Neurocrine Biosciences Community

Key Takeaways Expansion in formulary coverage and Phase III programs strengthens future revenue potential through increased patient access and new product approvals. Solid cash reserves provide flexibility for growth investments, supporting long-term earnings and strategic business development initiatives.

Key Takeaways Growth is driven by expanding flagship products into new patient segments, increased healthcare coverage, and strong adoption of new therapies for neurological disorders. Diversified late-stage pipeline and strategic investments in R&D, marketing, and business development support long-term revenue, margin, and portfolio growth.

Catalysts Pipeline Crenessity@ CRENESSITY Capsule 50/100 MG $766.66 packaging 50 MG 60u $45,999.60 packaging 100 MG 30u $22,999.80 Ingrezza@ Ingrezza (valbenazine) costs approximately $7,921 for 28 capsules of the 40mg strength and $8,702 for 28 capsules of the 80mg strength. INGREZZA Capsule 40 MG $310.80 INGREZZA SPRINKLE Capsule 40 MG $310.80 Other Products: Tetrabenazine Tablet 12.5 MG $62.52 Austedo Tablet 6 MG $100.06 Austedo XR Tablet 6 MG $100.06 Xenazine Tablet 12.5 MG $227.88 Assumptions Risks Risks and uncertainties associated with Neurocrine Biosciences' business and finances in general, risks and uncertainties associated with the commercialization of INGREZZA and CRENESSITY.

Key Takeaways Heavy dependence on INGREZZA and CRENESSITY exposes the company to regulatory, reimbursement, and competition risks that could threaten revenue growth and margins. Intensifying competition, payer consolidation, and potential R&D setbacks may erode market share, pricing power, and future earnings.